Omrix’s Biosurgical Products (OMRI)
Now I’m no surgeon, but I can guess that during surgery, there’s a lot of blood (actually, come to think of it, that’s part of the reason that I’m not a MD). Generally speaking, bleeding isn’t a good thing; Omrix’s biosurgical products and pipeline are designed to stop the bleeding (herein referred to by it’s clinical name, hemostasis).
Now how do you promote hemostasis in surgery? Well, the same way you do if you cut yourself when you’re shaving:
- If it’s a small cut, you let the proteins in the blood form a clot (scab). Essentially fibrinogen, a protein in the blood stream, combines with another protein in the blood stream, thrombin, to form a clot. Omrix’s Evicel (marketed as Quixil outside the U.S.) is essentially purified fibrinogen. Since it’s purified from human plasma, it contains naturally occurring proteins as part of its biological active component (BAC), which help form a clot that sticks to the wound better. Omrix is also in phase 3 trials for purified thrombin, the other component of the clot, which results in a much slower hemostasis (preferred in some types of surgery).
- If the cut is a little bigger or won’t stop on its own, you put a bandage on it. Omrix has designed a biodegradable patch that contains purified fibrinogen. The patch, which is in phase 1 clinical trials, is designed for high bleeding situations, like the emergency room, where the high flow/pressure from a wound rips a fibrinogen induced clot right off.
From my reading, it looks like they don’t have a patent on fibrinogen. Although they may have a patent on their purification process. Since they’re in a highly competitive field, they need to give the doctors a reason to buy their brand over any others. Omrix’s main advantage is that they purify fibrinogen out of human plasma while other competitors purify it out of cows, potentially causing the immune system to have to work overtime to fight off the perceived foreign infection. They’ve also packaged the fibrinogen in an easy to use form that can be stored at 4 degrees Celsius (refrigerator) for extended periods of time resulting in reduced waste of the product.
Omrix’s other competitive advantage in that they are good at purifying proteins out of human plasma. This same type of purification is used to create their passive imunotherapy product line, which I will talk about next time.
My first article, a Take on Affymetrix, is up at The Motley Fool. They’re trying to expand their biotechnology coverage, so here’s where you can find all their articles on stocks and personal finance although viewing them through the feed might be a better option since it will give you a little blurb that tells you what the article is about.
And grab my feed while you’re at it.
Filed under: Omrix Biopharmaceuticals (OMRI)